|Dr. Emil D. Kakkis M.D., Ph.D.||Pres, CEO & Director||1.43M||N/A||1960|
|Ms. Mardi C. Dier||Exec. VP & CFO||216.35k||N/A||1964|
|Mr. John Richard Pinion II||Chief Quality Operations Officer & Exec. VP of Translational Sciences||747.2k||N/A||1966|
|Dr. Camille L. Bedrosian||Chief Medical Officer & Exec. VP||844.42k||N/A||1953|
|Mr. Erik Harris||Exec. VP & Chief Commercial Officer||793.86k||N/A||1970|
|Mr. Theodore A. Huizenga||VP, Corp. Controller & Principal Accounting Officer||N/A||N/A||1971|
|Mr. Dennis Karl Huang||Chief Technical Operations Officer & Exec. VP||N/A||N/A||1965|
|Ms. Danielle Keatley||Sr. Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Karah Herdman Parschauer J.D.||Gen. Counsel & Exec. VP||N/A||N/A||1978|
|Mr. Ernie W. Meyer||Chief HR Officer & Exec. VP||N/A||N/A||1964|
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Ultragenyx Pharmaceutical Inc.’s ISS Governance QualityScore as of April 30, 2021 is 6. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 9.